Question 1

What is the difference between tirzepatide and semaglutide?

Accepted Answer

One receptor, and everything that follows from it. A 2021 head-to-head trial calls semaglutide a selective GLP-1 receptor agonist. Selective means it acts on one incretin receptor, the kind that answers the gut hormones released after a meal. A 2023 pharmacy article calls tirzepatide a dual GIP receptor and GLP-1 receptor agonist, which is two receptors rather than one. The second receptor is not a minor addition to the first. A 2020 laboratory study reported a greater degree of engagement of tirzepatide for the GIP receptor than the GLP-1 receptor. So the compound leans harder on the one receptor that semaglutide does not touch at all. That same study also set out the expectation that the difference would show up in people. Early phase trials in type 2 diabetes indicated that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP-1 receptor agonist. Whether the extra receptor is the reason for the trial results is proposed rather than shown, and the same caution applies to every mechanism argument on this page.

Question 2

Tirzepatide vs semaglutide: what did the head-to-head weight trial find?

Accepted Answer

A 2025 phase 3b trial put the question directly to 751 adults who had obesity but not type 2 diabetes. They were randomly assigned to the maximum tolerated dose of tirzepatide, which was 10 mg or 15 mg, or the maximum tolerated dose of semaglutide, which was 1.7 mg or 2.4 mg, injected once weekly for 72 weeks. At week 72 the least-squares mean percent change in weight stood at -20.2% in the tirzepatide group and -13.7% in the semaglutide group. The investigators concluded that tirzepatide was superior to semaglutide for reduction in body weight and waist circumference at week 72. One design feature governs how much that is worth. The trial was open-label, so participants and investigators both knew which injection was being given, and expectation is a documented influence on a weight endpoint. A blinded trial has not been published, which is a gap rather than a criticism of this one.

Question 3

What did the head-to-head diabetes trial find?

Accepted Answer

The earlier comparison ran in type 2 diabetes and measured blood sugar rather than weight. In an open-label, 40-week, phase 3 trial, 1,879 patients were randomly assigned to tirzepatide at 5 mg, 10 mg or 15 mg, or to semaglutide at 1 mg. The estimated mean change from baseline in glycated haemoglobin was -2.01, -2.24 and -2.30 percentage points across the three tirzepatide groups, against -1.86 percentage points with semaglutide. The investigators concluded that tirzepatide was noninferior and superior to semaglutide for that endpoint at 40 weeks. Two caveats travel with the number. The semaglutide comparison was a single assigned amount of 1 mg rather than the range tested on the other side, and the entry population had a mean glycated haemoglobin of 8.28%, which is a specific starting point rather than a general one.

Question 4

What did the real-world comparison show?

Accepted Answer

A 2024 cohort study looked at what happens outside a trial. It drew on health record data linked to dispensing information from a collective of US health care systems, covering adults who received semaglutide or tirzepatide between May 2022 and September 2023. Of 41,222 adults meeting the criteria, 18,386 remained after matching. Patients receiving tirzepatide were more likely to reach weight loss of 5%, 10% and 15%, with hazard ratios of 1.76, 2.54 and 3.24. Two details complicate that. Follow-up ended by discontinuation for 55.9% on tirzepatide and 52.5% on semaglutide, so more than half of each group stopped. And the authors note that future study is needed to understand differences in other important outcomes. A matched cohort cannot settle what a randomised trial would.

Question 5

Is tirzepatide better than semaglutide?

Accepted Answer

We do not rank compounds, and in this case the published findings make the refusal easy to explain rather than evasive. Three separate comparisons point the same direction on weight, and each one measures something slightly different. A 2024 JAMA review summarised the indirect evidence from meta-analysis: semaglutide was associated with 11.4% greater weight loss than placebo across 5 randomised trials and 4,421 participants, while tirzepatide 15 mg was associated with 12.4% greater weight loss across 6 trials and 1,972 participants. A 2023 JAMA review states that of the six approved long-term medicines, tirzepatide has the greatest effect, with mean weight loss of 21% at 72 weeks. What none of those establishes is what any individual reader would get, at what amount, for how long, at what cost in adverse effects. Larger on average and better for you are different questions.

Question 6

Which is safer, tirzepatide or semaglutide?

Accepted Answer

No trial among the research behind this page has compared the two with harm as its primary endpoint, so the honest answer begins with that gap rather than with a verdict. What exists is secondary reporting from comparisons designed around weight and blood sugar. The 2024 matched cohort recorded that rates of gastrointestinal adverse events were similar between groups. A 2021 diabetes trial reported that the safety profile of tirzepatide was consistent with GLP-1 receptor agonists. A 2024 review gives figures for the class rather than for either compound: nausea in 28% to 44% of patients, diarrhoea in 21% to 30%, and constipation in 11% to 24%. What is documented is therefore a class pattern with no reliable separation between the two. Long-term comparative harm is unstudied, and that is the finding, not a reassurance about either one.

Question 7

Is tirzepatide a GLP-1?

Accepted Answer

Partly, and the word partly is the whole answer. A 2025 review describes tirzepatide as a once-weekly dual agonist, acting on glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. So it acts on the GLP-1 receptor, and on a second receptor as well. Calling it a GLP-1 is therefore accurate and incomplete at the same time. A 2022 systematic review puts the same point as combining the dual agonism of GIP and GLP-1 receptors, and the distinction matters mainly when somebody compares it with a single-receptor compound. What the two receptors do, and why anybody built a molecule for both of them, is set out on the main tirzepatide page rather than repeated here.

Question 8

Is Mounjaro a GLP-1?

Accepted Answer

Same answer, because it is the same molecule under a trade name. A 2023 pharmacy journal article records that tirzepatide, marketed as Mounjaro, is a novel dual glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor agonist. So a product sold under that name acts on the GLP-1 receptor, which is why it gets grouped with GLP-1 medicines in reviews and in news coverage. It also acts on the GIP receptor, which single-receptor compounds do not. The practical consequence is small for a reader and larger for anyone reading a comparison table. A table that lists GLP-1 medicines and includes this one is not wrong, but it flattens the difference the head-to-head trials were built to measure, which is the difference the second receptor is supposed to produce.

Question 9

Tirzepatide vs retatrutide: how do they differ?

Accepted Answer

They are built around different receptor pairs, and they sit at opposite ends of the approval process. A 2024 review in Diabetes Care calls tirzepatide a GIP and GLP-1 receptor coagonist. It places retatrutide among investigational molecules that act on the glucagon and GLP-1 receptors at once. So one adds GIP to GLP-1. The other adds glucagon, a hormone that raises blood sugar. A 2025 review calls the wider strategy co-stimulation of GIP, glucagon, or amylin and other receptors alongside GLP-1. The difference that matters most is not the receptor list. Tirzepatide is approved at 5, 10 and 15 mg for two uses, while retatrutide is called investigational in the same literature. The comparison runs between a finished regulatory record and an unfinished one.

Question 10

Has tirzepatide been compared with retatrutide directly?

Accepted Answer

No trial among the research behind this page has given both to the same participants, so every comparison in circulation is assembled from separate trials in separate populations. That assembly is weaker than it looks. The tirzepatide figures come from trials of 751, 1,879 and 2,539 participants, each with its own entry criteria and its own comparator. Setting a number from one trial beside a number from another is not a head-to-head result, and the people recruited were not the same people. What can be said is the regulatory position. The 2023 JAMA list of six medicines approved for long-term use in obesity names tirzepatide and does not name retatrutide. A 2024 review classes retatrutide among investigational molecules.

Question 11

How does tirzepatide compare with other obesity medicines?

Accepted Answer

A 2024 JAMA review put the indirect comparisons in one place. Each figure is a margin over placebo, not over another compound. Orlistat was associated with 3.1% greater weight loss across 52 trials, phentermine-topiramate with 8.0%, naltrexone-bupropion with 4.1%, liraglutide with 4.7%, semaglutide with 11.4%, and tirzepatide 15 mg with 12.4%. Those trials differ in length, in who was let in and in how many took part. That is why the review prints them as separate lines and not as a ranking. The review also sets the context. These medicines are meant to be given alongside lifestyle programmes, and a companion review notes that behavioural programmes alone often produce 5% to 10% weight loss.

Question 12

What is the difference between a peptide and tirzepatide?

Accepted Answer

Tirzepatide belongs to the hormone-mimicking family that the word peptide usually points at in this context. A 2024 JAMA review groups it with liraglutide and semaglutide as nutrient-stimulated hormone-based medicines that mimic the actions of enteropancreatic hormones modifying central appetite regulation. So the question is usually really about supply rather than chemistry. A vial from a pharmacy and a vial from a research chemical supplier can carry the same name, and the difference lies in whether anyone independent has established what is inside. That is a sourcing question rather than a comparison between two compounds, and it is set out in detail on the buying page. What tirzepatide is, in plain terms, and what the trials measured, are covered on the main compound page.

Question 13

Are tirzepatide and semaglutide taken together?

Accepted Answer

No trial among the research behind this page has given both to the same participants. There is no result to report and no interaction to describe. Every head-to-head comparison in the literature assigned one or the other, never both. The nearest thing on record is a design idea, not a pairing of finished injections. A 2025 review describes co-stimulation of GIP, glucagon, or amylin and other receptors alongside GLP-1 as the route to extra effects. That is how a single molecule like tirzepatide was built. Read the distinction carefully. Two receptor actions engineered into one molecule, then tested in thousands of participants, is not the same thing as two separate injections taken together, which no study among the research behind this page has tested in anybody.

Question 14

How does the strength of the evidence compare?

Accepted Answer

Tirzepatide against semaglutide is the only pairing on this page with randomised head-to-head data, and there are two such trials. One enrolled 1,879 patients with type 2 diabetes over 40 weeks and the other 751 adults with obesity over 72 weeks. Both were open-label, and both compared assigned amounts rather than whatever a person might end up taking. Beneath those sits one matched cohort of 18,386 adults drawn from routine care, which is larger and weaker at the same time, because nobody was randomised into it. Tirzepatide against retatrutide has none of that. There is no randomised comparison, no cohort and no shared population, and the only solid statement available is that one is approved and the other is described as investigational. Ranking the two on effect would mean inventing a comparison no study we could find has run.

Tirzepatide comparisons and stacks